Arcus Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCUS research report →
About the company
Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
- CEO
- Terry J. Rosen
- IPO
- 2018
- Employees
- 601
- HQ
- Hayward, CA, US
Price Chart
- Market Cap
- $3.05B
- P/E
- -9.58
- P/S
- 12.94
- P/B
- 7.26
- EV/EBITDA
- -8.99
- Div Yield
- 0.00%
- Gross Margin
- 97.03%
- Op Margin
- -168.64%
- Net Margin
- -156.36%
- ROE
- -68.97%
- ROIC
- -49.69%
- Revenue
- $247.00M · -4.26%
- Net Income
- $-353,000,000 · -24.73%
- EPS
- $-3.29 · -4.78%
- Op Income
- $-386,000,000
- FCF YoY
- -175.00%
- 52W High
- $31.73
- 52W Low
- $8.03
- 50D MA
- $25.40
- 200D MA
- $21.76
- Beta
- 0.80
- Avg Volume
- 1.31M
Get TickerSpark's AI analysis on RCUS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 22, 26 | Jaen Juan C. | sell | 9,236 |
| Jun 23, 26 | Jaen Juan C. | sell | 14,067 |
| Jun 23, 26 | Jaen Juan C. | sell | 1,697 |
| Jun 24, 26 | Jaen Juan C. | sell | 6,431 |
| Jun 11, 26 | Lambert Nicole | other | 5,700 |
| Jun 11, 26 | Lambert Nicole | other | 16,900 |
| Jun 11, 26 | Machado Patrick | other | 5,700 |
| Jun 11, 26 | Machado Patrick | other | 16,900 |
| Jun 11, 26 | KANEKO YASUNORI | other | 5,700 |
| Jun 11, 26 | KANEKO YASUNORI | other | 16,900 |
Our RCUS coverage
Recent articles, reports, and earnings notes.
No research on RCUS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RCUS report →Similar companies
Peers in the same neighborhood.